BG63490B1 - Използване на лептин като инхибитор на пролиферацията на туморни клетки - Google Patents

Използване на лептин като инхибитор на пролиферацията на туморни клетки Download PDF

Info

Publication number: BG63490B1
Authority: BG; Bulgaria
Prior art keywords: leptin; active agent; cell proliferation; inhibiting; treatment
Prior art date: 1997-04-29

Application number

BG103832A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103832A (en

Inventor

Dalit Barkan

Batya Cohen

Menachem Rubinstein

Original Assignee

Yeda Research And Development Co. Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-29

Filing date

1999-10-25

Publication date

2002-03-29

1999-10-25 Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.

2000-10-31 Publication of BG103832A publication Critical patent/BG103832A/xx

2002-03-29 Publication of BG63490B1 publication Critical patent/BG63490B1/bg

Links

230000004663 cell proliferation Effects 0.000 title claims abstract description 54
239000003112 inhibitor Substances 0.000 title claims abstract description 21
210000004881 tumor cell Anatomy 0.000 title claims description 32
239000013543 active substance Substances 0.000 claims abstract description 43
150000003839 salts Chemical class 0.000 claims abstract description 21
239000012634 fragment Substances 0.000 claims abstract description 18
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 12
239000000203 mixture Substances 0.000 claims abstract description 8
239000004480 active ingredient Substances 0.000 claims abstract description 7
241000124008 Mammalia Species 0.000 claims abstract description 3
108010092277 Leptin Proteins 0.000 claims description 121
102000016267 Leptin Human genes 0.000 claims description 121
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 120
229940039781 leptin Drugs 0.000 claims description 116
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 76
102000004877 Insulin Human genes 0.000 claims description 38
108090001061 Insulin Proteins 0.000 claims description 38
229940125396 insulin Drugs 0.000 claims description 38
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 32
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 32
206010028980 Neoplasm Diseases 0.000 claims description 32
206010006187 Breast cancer Diseases 0.000 claims description 28
230000002401 inhibitory effect Effects 0.000 claims description 26
208000026310 Breast neoplasm Diseases 0.000 claims description 25
102100031775 Leptin receptor Human genes 0.000 claims description 24
108010019813 leptin receptors Proteins 0.000 claims description 24
102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 22
239000003102 growth factor Substances 0.000 claims description 18
101710201824 Insulin receptor substrate 1 Proteins 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
239000000018 receptor agonist Substances 0.000 claims description 14
229940044601 receptor agonist Drugs 0.000 claims description 14
230000036210 malignancy Effects 0.000 claims description 13
108090000695 Cytokines Proteins 0.000 claims description 11
102000004127 Cytokines Human genes 0.000 claims description 11
102000037865 fusion proteins Human genes 0.000 claims description 11
108020001507 fusion proteins Proteins 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
230000001419 dependent effect Effects 0.000 claims description 10
230000001404 mediated effect Effects 0.000 claims description 10
230000008747 mitogenic response Effects 0.000 claims description 10
108090000978 Interleukin-4 Proteins 0.000 claims description 8
108091005682 Receptor kinases Proteins 0.000 claims description 8
239000000758 substrate Substances 0.000 claims description 8
108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 claims description 6
102000001253 Protein Kinase Human genes 0.000 claims description 6
108010002335 Interleukin-9 Proteins 0.000 claims description 5
102000005962 receptors Human genes 0.000 claims description 5
108020003175 receptors Proteins 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 3
239000003966 growth inhibitor Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
230000037353 metabolic pathway Effects 0.000 claims 3
101100205088 Caenorhabditis elegans iars-1 gene Proteins 0.000 claims 2
101150030450 IRS1 gene Proteins 0.000 claims 2
101100232738 Gallus gallus IFNL3 gene Proteins 0.000 claims 1
101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 1
239000000565 sealant Substances 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 21
102000004169 proteins and genes Human genes 0.000 abstract description 20
239000000556 agonist Substances 0.000 abstract description 4
230000015572 biosynthetic process Effects 0.000 abstract description 2
238000010790 dilution Methods 0.000 abstract 1
239000012895 dilution Substances 0.000 abstract 1
238000005755 formation reaction Methods 0.000 abstract 1
230000003211 malignant effect Effects 0.000 abstract 1
239000002562 thickening agent Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 57
108091003079 Bovine Serum Albumin Proteins 0.000 description 22
239000012091 fetal bovine serum Substances 0.000 description 22
108090000765 processed proteins & peptides Proteins 0.000 description 18
230000035755 proliferation Effects 0.000 description 18
235000018102 proteins Nutrition 0.000 description 18
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 14
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 12
102000003746 Insulin Receptor Human genes 0.000 description 9
108010001127 Insulin Receptor Proteins 0.000 description 9
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
101001063890 Mus musculus Leptin Proteins 0.000 description 8
238000000034 method Methods 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 7
230000026731 phosphorylation Effects 0.000 description 7
238000006366 phosphorylation reaction Methods 0.000 description 7
238000010186 staining Methods 0.000 description 7
241001529936 Murinae Species 0.000 description 6
239000013078 crystal Substances 0.000 description 6
238000003235 crystal violet staining Methods 0.000 description 6
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
239000011324 bead Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Chemical class 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
210000001789 adipocyte Anatomy 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
201000008274 breast adenocarcinoma Diseases 0.000 description 3
125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000037406 food intake Effects 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000012679 serum free medium Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
-1 DNA or RNA Chemical class 0.000 description 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000000270 basal cell Anatomy 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
239000007952 growth promoter Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
GMRGSBAMMMVDGG-GUBZILKMSA-N Asn-Arg-Arg Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N GMRGSBAMMMVDGG-GUBZILKMSA-N 0.000 description 1
APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 1
FBODFHMLALOPHP-GUBZILKMSA-N Asn-Lys-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O FBODFHMLALOPHP-GUBZILKMSA-N 0.000 description 1
XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
KPENUVBHAKRDQR-GUBZILKMSA-N Cys-His-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPENUVBHAKRDQR-GUBZILKMSA-N 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
XEKAJTCACGEBOK-KKUMJFAQSA-N Glu-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XEKAJTCACGEBOK-KKUMJFAQSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
101001063991 Homo sapiens Leptin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 1
UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
UIIMIKFNIYPDJF-WDSOQIARSA-N Leu-Trp-Met Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)[C@@H](N)CC(C)C)=CNC2=C1 UIIMIKFNIYPDJF-WDSOQIARSA-N 0.000 description 1
QUYCUALODHJQLK-CIUDSAMLSA-N Lys-Asp-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUYCUALODHJQLK-CIUDSAMLSA-N 0.000 description 1
OVIVOCSURJYCTM-GUBZILKMSA-N Lys-Asp-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OVIVOCSURJYCTM-GUBZILKMSA-N 0.000 description 1
XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 description 1
UYDDNEYNGGSTDW-OYDLWJJNSA-N Met-Trp-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N UYDDNEYNGGSTDW-OYDLWJJNSA-N 0.000 description 1
108010079364 N-glycylalanine Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
WJKJJGXZRHDNTN-UWVGGRQHSA-N Tyr-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 WJKJJGXZRHDNTN-UWVGGRQHSA-N 0.000 description 1
ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001621 anti-mitogenic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
108010025306 histidylleucine Proteins 0.000 description 1
102000044162 human IGF1 Human genes 0.000 description 1
102000049953 human LEP Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
102000005861 leptin receptors Human genes 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
108700010839 phage proteins Proteins 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000012868 site-directed mutagenesis technique Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000035924 thermogenesis Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BG103832A 1997-04-29 1999-10-25 Използване на лептин като инхибитор на пролиферацията на туморни клетки BG63490B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL12073397A IL120733A0 (en)	1997-04-29	1997-04-29	Leptin as an inhibitor of cell proliferation
PCT/IL1998/000196 WO1998048831A1 (en)	1997-04-29	1998-04-26	Leptin as an inhibitor of tumor cell proliferation

Publications (2)

Publication Number	Publication Date
BG103832A BG103832A (en)	2000-10-31
BG63490B1 true BG63490B1 (bg)	2002-03-29

Family

ID=11070075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103832A BG63490B1 (bg)	1997-04-29	1999-10-25	Използване на лептин като инхибитор на пролиферацията на туморни клетки

Country Status (25)

Country	Link
US (1)	US7109159B1 (no)
EP (1)	EP0981365B1 (no)
JP (1)	JP4330662B2 (no)
KR (1)	KR100507731B1 (no)
CN (1)	CN1168497C (no)
AR (1)	AR012626A1 (no)
AT (1)	ATE283702T1 (no)
AU (1)	AU742927B2 (no)
BG (1)	BG63490B1 (no)
CA (1)	CA2288238A1 (no)
CZ (1)	CZ299872B6 (no)
DE (1)	DE69827942T2 (no)
EA (1)	EA002353B1 (no)
EE (1)	EE04801B1 (no)
ES (1)	ES2232944T3 (no)
HU (1)	HUP0002427A3 (no)
IL (2)	IL120733A0 (no)
NO (1)	NO322304B1 (no)
NZ (1)	NZ500589A (no)
PL (1)	PL195275B1 (no)
PT (1)	PT981365E (no)
SK (1)	SK284848B6 (no)
UA (1)	UA66793C2 (no)
WO (1)	WO1998048831A1 (no)
ZA (1)	ZA983608B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7208572B2 (en)	1998-08-21	2007-04-24	Albany Medical College	Leptin-related peptides
US6777388B1 (en)	1998-08-21	2004-08-17	Clf Medical Technology Acceleration Program, Inc.	Leptin-related peptides
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
IL132312A0 (en) *	1999-09-05	2001-03-19	Yeda Res & Dev	Use of leptin in inhibition of endothelial cell proliferation
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
KR20140011431A (ko)	2004-02-11	2014-01-28	아밀린 파마슈티칼스, 엘엘씨.	선택가능한 특성을 갖는 하이브리드 폴리펩티드
US8969291B2 (en)	2004-10-08	2015-03-03	Enzo Therapeutics, Inc.	Methods for decreasing leptin levels or activity for treating inflammation
US7863240B2 (en) *	2004-10-08	2011-01-04	Enzo Therapeutics, Inc.	Methods and uses of leptin in hepatocellular carcinoma
US20090286723A1 (en)	2005-02-11	2009-11-19	Amylin Pharmaceuticals, Inc.	Hybrid Polypeptides with Selectable Properties
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en)	2005-02-11	2006-08-17	Amylin Pharmaceuticals, Inc.	Gip analog and hybrid polypeptides with selectable properties
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
US8227408B2 (en) *	2005-09-07	2012-07-24	Neurotez, Inc.	Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) *	2005-09-07	2014-05-06	Nikolaos Tezapsidis	Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2712606A1 (en)	2008-02-08	2009-08-13	Ambrx, Inc.	Modified leptin polypeptides and their uses
CN102099048A (zh) *	2008-05-21	2011-06-15	纽若泰兹公司	用于治疗与神经原纤维缠结有关的进行性认知障碍的方法
US20100316639A1 (en)	2009-06-16	2010-12-16	Genentech, Inc.	Biomarkers for igf-1r inhibitor therapy
TWI824372B (zh)	2015-10-12	2023-12-01	美商再生元醫藥公司	活化瘦素受體的抗原結合蛋白
EP3538554A1 (en)	2016-11-08	2019-09-18	Regeneron Pharmaceuticals, Inc.	Antigen-binding proteins that antagonize leptin receptor
CN111542540A (zh)	2017-12-18	2020-08-14	瑞泽恩制药公司	结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法
CN112040980A (zh)	2018-04-06	2020-12-04	瑞泽恩制药公司	用于治疗代谢功能障碍或低瘦蛋白血症的瘦蛋白受体激动剂抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0836479A2 (en) *	1995-06-30	1998-04-22	Eli Lilly And Company	Methods for treating diabetes
CA2232193A1 (en) *	1995-09-19	1997-03-27	Brigitte Elisabeth Schoner	Dna encoding medicinal proteins
EP1731164A1 (en) *	1996-01-23	2006-12-13	Indevus Pharmaceuticals, Inc.	Methods for using the obese gene and its gene product to stimulate hematopoietic development

1997
- 1997-04-29 IL IL12073397A patent/IL120733A0/xx unknown
1998
- 1998-04-26 KR KR10-1999-7009705A patent/KR100507731B1/ko not_active Expired - Fee Related
- 1998-04-26 CN CNB988066920A patent/CN1168497C/zh not_active Expired - Fee Related
- 1998-04-26 EP EP98917580A patent/EP0981365B1/en not_active Expired - Lifetime
- 1998-04-26 JP JP54678798A patent/JP4330662B2/ja not_active Expired - Fee Related
- 1998-04-26 AT AT98917580T patent/ATE283702T1/de active
- 1998-04-26 EA EA199900981A patent/EA002353B1/ru not_active IP Right Cessation
- 1998-04-26 AU AU70762/98A patent/AU742927B2/en not_active Ceased
- 1998-04-26 NZ NZ500589A patent/NZ500589A/xx not_active IP Right Cessation
- 1998-04-26 PT PT98917580T patent/PT981365E/pt unknown
- 1998-04-26 HU HU0002427A patent/HUP0002427A3/hu unknown
- 1998-04-26 CA CA002288238A patent/CA2288238A1/en not_active Abandoned
- 1998-04-26 UA UA99116415A patent/UA66793C2/uk unknown
- 1998-04-26 CZ CZ0384899A patent/CZ299872B6/cs not_active IP Right Cessation
- 1998-04-26 ES ES98917580T patent/ES2232944T3/es not_active Expired - Lifetime
- 1998-04-26 DE DE69827942T patent/DE69827942T2/de not_active Expired - Lifetime
- 1998-04-26 PL PL98336582A patent/PL195275B1/pl not_active IP Right Cessation
- 1998-04-26 US US09/403,897 patent/US7109159B1/en not_active Expired - Fee Related
- 1998-04-26 WO PCT/IL1998/000196 patent/WO1998048831A1/en active IP Right Grant
- 1998-04-26 SK SK1471-99A patent/SK284848B6/sk not_active IP Right Cessation
- 1998-04-26 EE EEP199900510A patent/EE04801B1/xx not_active IP Right Cessation
- 1998-04-29 AR ARP980102003A patent/AR012626A1/es unknown
- 1998-04-29 ZA ZA983608A patent/ZA983608B/xx unknown
1999
- 1999-10-25 BG BG103832A patent/BG63490B1/bg unknown
- 1999-10-28 IL IL132633A patent/IL132633A/en not_active IP Right Cessation
- 1999-10-28 NO NO19995267A patent/NO322304B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EE04801B1 (et)	2007-04-16
ZA983608B (en)	1998-11-02
KR20010012080A (ko)	2001-02-15
EA199900981A1 (ru)	2000-04-24
NO995267D0 (no)	1999-10-28
NO995267L (no)	1999-12-28
CZ384899A3 (cs)	2000-06-14
KR100507731B1 (ko)	2005-08-10
ES2232944T3 (es)	2005-06-01
PL195275B1 (pl)	2007-08-31
HUP0002427A3 (en)	2003-02-28
EP0981365B1 (en)	2004-12-01
US7109159B1 (en)	2006-09-19
CN1261802A (zh)	2000-08-02
NZ500589A (en)	2001-03-30
BG103832A (en)	2000-10-31
CA2288238A1 (en)	1998-11-05
DE69827942D1 (de)	2005-01-05
CZ299872B6 (cs)	2008-12-17
NO322304B1 (no)	2006-09-11
IL120733A0 (en)	1997-08-14
EA002353B1 (ru)	2002-04-25
DE69827942T2 (de)	2005-12-08
SK284848B6 (sk)	2006-01-05
EP0981365A1 (en)	2000-03-01
SK147199A3 (en)	2000-06-12
IL132633A (en)	2007-07-04
AU7076298A (en)	1998-11-24
JP4330662B2 (ja)	2009-09-16
PT981365E (pt)	2005-03-31
JP2001524968A (ja)	2001-12-04
PL336582A1 (en)	2000-07-03
HUP0002427A2 (hu)	2000-12-28
UA66793C2 (uk)	2004-06-15
HK1028350A1 (en)	2001-02-16
AR012626A1 (es)	2000-11-08
CN1168497C (zh)	2004-09-29
ATE283702T1 (de)	2004-12-15
AU742927B2 (en)	2002-01-17
EE9900510A (et)	2000-06-15
WO1998048831A1 (en)	1998-11-05

Publication	Publication Date	Title
BG63490B1 (bg)	2002-03-29	Използване на лептин като инхибитор на пролиферацията на туморни клетки
EP3062881B1 (en)	2019-10-02	Cancer models and associated methods
EP0597503B1 (en)	1998-10-14	ECK receptor ligands
KR100898765B1 (ko)	2009-05-20	성장인자 복합체
HUT53936A (en)	1990-12-28	Process for producing carrier proteins for insulin-like growth factors
KR20120082909A (ko)	2012-07-24	합성 마이오스타틴 펩티드 길항제
US20060211606A1 (en)	2006-09-21	Peptides
EP0580752A1 (en)	1994-02-02	Human bone derived insulin like growth factor binding protein
JP4094814B2 (ja)	2008-06-04	血管新生抑制剤
KR20080021588A (ko)	2008-03-07	메카노 성장 인자 펩티드 및 이들의 용도
JP2004533235A5 (no)	2006-01-05
KR20220145870A (ko)	2022-10-31	뉴레귤린, 및 조성물을 사용함으로써 심부전을 예방, 치료 또는 지연시키기 위한 방법
MXPA99009972A (en)	2000-09-04	Leptin as an inhibitor of tumor cell proliferation
JP4583763B2 (ja)	2010-11-17	切断型２４ｋＤａ塩基性線維芽細胞成長因子
HK1227790B (en)	2020-05-22	Cancer models and associated methods
HK1227790A1 (en)	2017-10-27	Cancer models and associated methods